317 related articles for article (PubMed ID: 6890758)
1. Prostaglandins and the management of congenital heart disease.
Taylor WJ; Alpert BS
Am Fam Physician; 1982 Dec; 26(6):127-32. PubMed ID: 6890758
[TBL] [Abstract][Full Text] [Related]
2. The ductus arteriosus: why and how to manipulate its patency.
Drummond WH; Bucciarelli RL; Gessner IH
J Fla Med Assoc; 1983 Sep; 70(9):788-93. PubMed ID: 6355376
[No Abstract] [Full Text] [Related]
3. Cardiovascular therapy in the newborn.
Sandor GG
Clin Invest Med; 1985; 8(4):360-7. PubMed ID: 3907921
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological manipulation of the ductus arteriosus.
Silove ED
Arch Dis Child; 1986 Sep; 61(9):827-9. PubMed ID: 3767410
[No Abstract] [Full Text] [Related]
5. Clinical use of prostaglandins and prostaglandin synthetase inhibitors in cardiac problems of the newborn.
Olley PM; Coceani F; Rowe RD; Swyer PR
Adv Prostaglandin Thromboxane Res; 1980; 7():913-6. PubMed ID: 6768235
[No Abstract] [Full Text] [Related]
6. Comments on the pharmacologic manipulation of the ductus arteriosus in newborns.
Rowe RD
Adv Prostaglandin Thromboxane Res; 1978; 4():383-5. PubMed ID: 645513
[No Abstract] [Full Text] [Related]
7. Congenital heart disease and respiratory distress syndrome. Reversal of indomethacin closure of patent ductus arteriosus by prostaglandin therapy in a preterm infant.
Strauss A; Modanlou HD; Gyepes M; Wittner R
Am J Dis Child; 1982 Oct; 136(10):934-6. PubMed ID: 6889810
[TBL] [Abstract][Full Text] [Related]
8. [Prostaglandin treatment of ductus-dependent congenital heart defects].
Olsson B; Björkhem G; Lundström NR
Lakartidningen; 1984 Oct; 81(40):3619-22. PubMed ID: 6541738
[No Abstract] [Full Text] [Related]
9. Evaluation of alprostadil (prostaglandin E1) in the management of congenital heart disease in infancy.
Heymann MA; Clyman RI
Pharmacotherapy; 1982; 2(3):148-55. PubMed ID: 6763200
[TBL] [Abstract][Full Text] [Related]
10. [Value of prostaglandin E1 in cardiac malformations in the newborn infant].
Sassolas F; Bozio A; Andre M; Jocteur-Monrozier D; Champsaur G; Normand J
Pediatrie; 1984 Jun; 39(4):245-52. PubMed ID: 6504667
[TBL] [Abstract][Full Text] [Related]
11. Role of prostaglandin E1 and E2 in the management of neonatal heart disease.
Olley PM; Coceani F; Rowe RD
Adv Prostaglandin Thromboxane Res; 1978; 4():345-53. PubMed ID: 645511
[No Abstract] [Full Text] [Related]
12. Medical treatment of the ductus arteriosus.
Rudolph AM; Heymann MA
Hosp Pract; 1977 Feb; 12(2):57-65. PubMed ID: 557025
[TBL] [Abstract][Full Text] [Related]
13. [Analogs of prostaglandin-related substances and inhibitors of their formation and metabolism. Clinical application to the pediatric field--arteries and prostaglandins].
Honda S
Nihon Rinsho; 1985 Mar; 43(3):603-7. PubMed ID: 3892092
[No Abstract] [Full Text] [Related]
14. [The pharmacological manipulation of Botallo's duct in the duct-dependent congenital cardiopathies and in the preterm infants with respiratory distress. A review and personal findings].
Distefano G
Minerva Pediatr; 2005 Feb; 57(1):21-34. PubMed ID: 15791199
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandin E1 in neonates with critical congenital heart disease.
Dungan WT; Norton JB; Readinger RI; Sotomora RF
J Ark Med Soc; 1982 Oct; 79(5):167-70. PubMed ID: 6183249
[No Abstract] [Full Text] [Related]
16. Morphologic features of the ductus arteriosus after prostaglandin E1 administration for ductus-dependent congenital heart defects.
Park IS; Nihill MR; Titus JL
J Am Coll Cardiol; 1983 Feb; 1(2 Pt 1):471-5. PubMed ID: 6681824
[No Abstract] [Full Text] [Related]
17. [Prolonged prostaglandin E-1 therapy of newborn infants with congenital heart defects].
Kertész E; Hencz P; Tekulics P; Beviz J; Száva J; Matkó I; Kovács G
Orv Hetil; 1980 May; 121(20):1197-9. PubMed ID: 7413203
[No Abstract] [Full Text] [Related]
18. [Anesthesia for neonates and young infants with ductus dependent cardiac malformations treated with prostaglandin E1].
Fujii S; Nagai I; Yonei A; Sari A; Baba K
Masui; 1984 May; 33(5):545-9. PubMed ID: 6540818
[No Abstract] [Full Text] [Related]
19. [Skeletal side effects of treatment with prostaglandin E1].
Persigehl M; Hövels-Gürich H; von Bernuth G
Rofo; 1984 Oct; 141(4):427-30. PubMed ID: 6436918
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of ductus-dependent congenital heart diseases with prostaglandin E1].
Lillquist K
Ugeskr Laeger; 1979 Jul; 141(28):1915-6. PubMed ID: 473414
[No Abstract] [Full Text] [Related]
[Next] [New Search]
